Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review | Zendy

Charles Fogarty | Zendy; Patricia Buchanan | Zendy; Michel Aubier | Zendy; Malik Baz | Zendy; Dirkie van Rensburg | Zendy; Manickam Rangaraju | Zendy; Roomi Nusrat | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review

Author(s) -

Charles Fogarty,

Patricia Buchanan,

Michel Aubier,

Malik Baz,

Dirkie van Rensburg,

Manickam Rangaraju,

Roomi Nusrat

Publication year - 2005

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2005.01.003

Subject(s) - telithromycin , medicine , streptococcus pneumoniae , chronic bronchitis , ketolide , bronchitis , respiratory tract infections , erythromycin , pneumonia , penicillin , sinusitis , gastroenterology , antibiotics , microbiology and biotechnology , surgery , respiratory system , clarithromycin , helicobacter pylori , biology

A pooled analysis of 14 Phase III studies was performed to establish the clinical and bacteriologic efficacy of telithromycin 800 mg once daily in the treatment of pneumococcal community-acquired respiratory tract infections (RTIs).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research